According to the 26th announcement by CFDA in 2013: GMP inspection notice (No. 8) of pharmaceutical product, Kawin Technology’s recombinant human interferon alfa-2b products - injection, vaginal effervescent tablets, lyophilized powder and small volume injection all comply with the latest GMP (2010 version) requirements. Kawin Technology has thereby acquired the GMP certificate (certificate No.: CN20130242).

Kawin Technology Acquires Beijing Certificate of Standardization of Safety in Production Kawin Technology awards“Beijing Enterprise Technology Center”